Molecular profiling of rare thymoma using next-generation sequencing: meta-analysis

1 Cowen D, Richaud P, Mornex F, Bachelot T, Jung GM, Mirabel X, et al. Thymoma: results of a multicentric retrospective series of 149 non-metastatic irradiated patients and review of the literature. FNCLCC trialists. Federation Nationale des Centres de Lutte Contre le Cancer. Radiother Oncol 1995; 34: 9-16. doi: 10.1016/0167-8140(94)01493-m Cowen D Richaud P Mornex F Bachelot T Jung GM Mirabel X et al Thymoma: results of a multicentric retrospective series of 149 non-metastatic irradiated patients and review of the literature. FNCLCC trialists. Federation Nationale des Centres de Lutte Contre le Cancer. Radiother Oncol 1995 34 9 16 doi 10.1016/0167-8140(94)01493-mOpen DOISearch in Google Scholar

2 Levine GD, Rosai J. Thymic hyperplasia and neoplasia: a review of current concepts. Human Pathology 1978; 9: 495-515. doi: 10.1016/s0046-8177(78)80131-2 Levine GD Rosai J Thymic hyperplasia and neoplasia: a review of current concepts. Human Pathology 1978 9 495 515 doi 10.1016/s0046-8177(78)80131-2Open DOISearch in Google Scholar

3 Falkson CB, Bezjak A, Darling G, Gregg R, Malthaner R, Maziak DE, et al. The management of thymoma: a systematic review and practice guideline. J Thorac Oncol 2009; 4: 911-9. doi: 10.1097/jto.0b013e3181a4b8e0 Falkson CB Bezjak A Darling G Gregg R Malthaner R Maziak DE et al The management of thymoma: a systematic review and practice guideline. J Thorac Oncol 2009 4 911 9 doi 10.1097/jto.0b013e3181a4b8e0Open DOISearch in Google Scholar

4 Okumura M, Ohta M, Tateyama H, Nakagawa K, Matsumura A, Maeda H, et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer 2002; 94: 624-32. doi: 10.1002/cncr.10226 Okumura M Ohta M Tateyama H Nakagawa K Matsumura A Maeda H et al The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer 2002 94 624 32 doi 10.1002/cncr.10226Open DOISearch in Google Scholar

5 Engels EA, Pfeiffer RM. Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer 2003; 105: 546-51. doi: 10.1002/ijc.11099 Engels EA Pfeiffer RM Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer 2003 105 546 51 doi 10.1002/ijc.11099Open DOISearch in Google Scholar

6 Tomaszek S, Wigle DA, Keshavjee S, Fischer S. Thymomas: review of current clinical practice. Ann Thorac Surg 2009; 87: 1973-80. doi: 10.1016/j. athoracsur.2008.12.095 Tomaszek S Wigle DA Keshavjee S Fischer S Thymomas: review of current clinical practice. Ann Thorac Surg 2009 87 1973 80 doi 10.1016/j.athoracsur.2008.12.095Open DOISearch in Google Scholar

7 Chau NG, Kim ES, Wistuba I. The multidisciplinary approach to thymoma: combining molecular and clinical approaches. J Thorac Oncol 2010; 5: S313-7. doi: 10.1097/JTO.0b013e3181f20d9a Chau NG Kim ES Wistuba I The multidisciplinary approach to thymoma: combining molecular and clinical approaches. J Thorac Oncol 2010 5 S313 7 doi 10.1097/JTO.0b013e3181f20d9aOpen DOISearch in Google Scholar

8 Miyamoto K, Acoba JD. Thymomas and thymic carcinomas: a review on pathology, presentation, staging, treatment, and novel systemic therapies. EMJ Respir 2017; 5: 100-7. doi: 10.33590/emjrespir/10310358 Miyamoto K Acoba JD Thymomas and thymic carcinomas: a review on pathology, presentation, staging, treatment, and novel systemic therapies. EMJ Respir 2017 5 100 7 doi 10.33590/emjrespir/10310358Open DOISearch in Google Scholar

9 Peric J, Samaradzic N, Skodric Trifunovic V, Tosic N, Stojsic J, Pavlovic S, et al. Genomic profiling of thymoma using a targeted high-throughput approach. Arch Med Sci 2020. doi: 10.5114/aoms.2020.96537 Peric J Samaradzic N Skodric Trifunovic V Tosic N Stojsic J Pavlovic S et al Genomic profiling of thymoma using a targeted high-throughput approach. Arch Med Sci 2020 doi 10.5114/aoms.2020.96537Open DOISearch in Google Scholar

10 Slatko BE, Gardner AF, Ausubel FM. Overview of next-generation sequencing technologies. Curr Protoc Mol Biol 2018; 122: e59. doi: 10.1002/cpmb.59 Slatko BE Gardner AF Ausubel FM Overview of next-generation sequencing technologies. Curr Protoc Mol Biol 2018 122 e59 doi 10.1002/cpmb.59Open DOISearch in Google Scholar

11 Duncavage EJ, Abel HJ, Szankasi P, Kelley TW, Pfeifer JD. Targeted next generation sequencing of clinically significant gene mutations and translocations in leukemia. Mod Pathol 2012; 25: 795-804. doi: 10.1038/modpathol.2012.29 Duncavage EJ Abel HJ Szankasi P Kelley TW Pfeifer JD Targeted next generation sequencing of clinically significant gene mutations and translocations in leukemia. Mod Pathol 2012 25 795 804 doi 10.1038/modpathol.2012.29Open DOISearch in Google Scholar

12 Xu H, DiCarlo J, Satya RV, Peng Q, Wang Y. Comparison of somatic mutation calling methods in amplicon and whole exome sequence data. BMC Genomics 2014; 15: 244. doi: 10.1186/1471-2164-15-244 Xu H DiCarlo J Satya RV Peng Q Wang Y Comparison of somatic mutation calling methods in amplicon and whole exome sequence data. BMC Genomics 2014 15 244 doi 10.1186/1471-2164-15-244Open DOISearch in Google Scholar

13 Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, et al. OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol 2017; 2017: PO.17.00011. doi: 10.1200/PO.17.00011 Chakravarty D Gao J Phillips SM Kundra R Zhang H Wang J et al OncoKB: A Precision Oncology Knowledge Base. JCO Precis Oncol 2017 2017 PO.17.00011 doi 10.1200/PO.17.00011Open DOISearch in Google Scholar

14 Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidem 2009; 62: e1-34. doi: 10.1016/j.jclinepi.2009.06.006 Liberati A Altman DG Tetzlaff J Mulrow C Gotzsche PC Ioannidis JP et al The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidem 2009 62 e1 34 doi 10.1016/j.jclinepi.2009.06.006Open DOISearch in Google Scholar

15 Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page M J, et al. A Cochrane handbook for systematic reviews of interventions. Cochrane handbook for systematic reviews of interventions. 2019. (cited 2022 Dec 19). Available at: https://training.cochrane.org/handbook Higgins JP Thomas J Chandler J Cumpston M Li T Page M J et al A Cochrane handbook for systematic reviews of interventions. Cochrane handbook for systematic reviews of interventions. 2019 (cited 2022 Dec 19). Available at: https://training.cochrane.org/handbookSearch in Google Scholar

16 Cohrain Training. RevMan 5. (accessed 2021 Aug 3). Available at: https://training.cochrane.org/online-learning/core-software-cochrane-reviews/revman/revman-5-download Cohrain Training RevMan 5 accessed 2021 Aug 3 Available at https://training.cochrane.org/online-learning/core-software-cochrane-reviews/revman/revman-5-downloadSearch in Google Scholar

17 Girard N, Basse C, Schrock A, Ramkissoon S, Killian K, Ross JS. Comprehensive genomic profiling of 274 thymic epithelial tumors unveils oncogenic pathways and predictive biomarkers. Oncologist 2022; 27: 919-29. doi: 10.1093/oncolo/oyac115 Girard N Basse C Schrock A Ramkissoon S Killian K Ross JS Comprehensive genomic profiling of 274 thymic epithelial tumors unveils oncogenic pathways and predictive biomarkers. Oncologist 2022 27 919 29 doi 10.1093/oncolo/oyac115Open DOISearch in Google Scholar

18 Szpechcinski A, Szolkowska M, Winiarski S, Lechowicz U, Wisniewski P, Knetki-Wroblewska M. Targeted next-generation sequencing of thymic epithelial tumours revealed pathogenic variants in KIT, ERBB2, KRAS, and TP53 in 30% of thymic carcinomas. Cancers 2022; 14: 3388. doi: 10.3390/cancers14143388 Szpechcinski A Szolkowska M Winiarski S Lechowicz U Wisniewski P Knetki-Wroblewska M Targeted next-generation sequencing of thymic epithelial tumours revealed pathogenic variants in KIT, ERBB2, KRAS, and TP53 in 30% of thymic carcinomas. Cancers 2022 14 3388 doi 10.3390/cancers14143388Open DOISearch in Google Scholar

19 GeneCards^® The Human Gene Database. (Updated: 2023 Jan 10). Available at: https://www.genecards.org/ GeneCards^® The Human Gene Database Updated 2023 Jan 10 Available at https://www.genecards.org/Search in Google Scholar

20 Müllauer L. GTF2I gene mutation – a driver of thymoma pathogenesis. Mediastinum 2017; 1: 11. doi: 10.21037/med.2017.11.03 Müllauer L GTF2I gene mutation – a driver of thymoma pathogenesis. Mediastinum 2017 1 11 doi 10.21037/med.2017.11.03Open DOISearch in Google Scholar

21 Feng Y, Lei Y, Wu X, Huang Y, Rao H, Zhang Y, et al. GTF2I mutation frequently occurs in more indolent thymic epithelial tumors and predicts better prognosis. Lung Cancer 2017; 110: 48-52. doi: 10.1016/j.lungcan.2017.05.02022 Feng Y Lei Y Wu X Huang Y Rao H Zhang Y et al GTF2I mutation frequently occurs in more indolent thymic epithelial tumors and predicts better prognosis. Lung Cancer 2017 110 48 52 doi 10.1016/j.lungcan.2017.05.02022Open DOISearch in Google Scholar

22 Radovich M, Pickering CR, Felau I, Ha G, Zhang H, Jo H, et al. The integrated genomic landscape of thymic epithelial tumors. Cancer Cell 2018; 33: 244-58.e10. doi: 10.1016/j.ccell.2018.01.003 Radovich M Pickering CR Felau I Ha G Zhang H Jo H et al The integrated genomic landscape of thymic epithelial tumors. Cancer Cell 2018 33 244 58e10 doi 10.1016/j.ccell.2018.01.003Open DOISearch in Google Scholar

23 Liu D, Zhang P, Zhao J, Yang L, Wang W. Identification of molecular characteristics and new prognostic targets for thymoma by multiomics analysis. BioMed Res Int 2021; 2021: Article ID 5587441, 1-15. doi: 10.1155/2021/5587441 Liu D Zhang P Zhao J Yang L Wang W Identification of molecular characteristics and new prognostic targets for thymoma by multiomics analysis. BioMed Res Int 2021 2021 Article ID 5587441 1 15 doi 10.1155/2021/5587441Open DOISearch in Google Scholar

24 TCGA’s Study of Thymoma. (cited 2022 Dec 5). Available at: https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga/studied-cancers/thymoma TCGA’s Study of Thymoma cited 2022 Dec 5 Available at https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga/studied-cancers/thymomaSearch in Google Scholar

25 Venuta F, Rendina EA, Anile M, de Giacomo T, Vitolo D, Coloni GF. Thymoma and thymic carcinoma. Gen Thorac Cardiovasc Surg 2012; 60: 1-12. doi: 10.1007/s11748-011-0814-0 Venuta F Rendina EA Anile M de Giacomo T Vitolo D Coloni GF Thymoma and thymic carcinoma Gen Thorac Cardiovasc Surg 2012 60 1 12 doi 10.1007/s11748-011-0814-0Open DOISearch in Google Scholar

26 Petrini I, Meltzer PS, Kim IK, Lucchi M, Park KS, Fontanini G, et al. A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nature Genetics 2014; 46: 844-9. doi: 10.1038/ng.3016 Petrini I Meltzer PS Kim IK Lucchi M Park KS Fontanini G et al A specific missense mutation in GTF2I occurs at high frequency in thymic epithelial tumors. Nature Genetics 2014 46 844 9 doi 10.1038/ng.3016Open DOISearch in Google Scholar

27 Higuchi R, Goto T, Hirotsu Y, Yokoyama Y, Nakagomi T, Otake S, et al. Primary driver mutations in GTF2I specific to the development of thymomas. Cancers 2020; 12: 1-12. doi: 10.3390/cancers12082032 Higuchi R Goto T Hirotsu Y Yokoyama Y Nakagomi T Otake S et al Primary driver mutations in GTF2I specific to the development of thymomas. Cancers 2020 12 1 12 doi 10.3390/cancers12082032Open DOISearch in Google Scholar

28 Liang NX, Liu L, Huang C, Liu HS, Guo C, Li J, et al. Transcriptomic and mutational analysis discovering distinct molecular characteristics among chinese thymic epithelial tumor patients. Front Oncol 2021; 11: 647512. doi: 10.3389/fonc.2021.647512 Liang NX Liu L Huang C Liu HS Guo C Li J et al Transcriptomic and mutational analysis discovering distinct molecular characteristics among chinese thymic epithelial tumor patients. Front Oncol 2021 11 647512 doi 10.3389/fonc.2021.647512Open DOISearch in Google Scholar

29 Hafner A, Bulyk ML, Jambhekar A, Lahav G. The multiple mechanisms that regulate p53 activity and cell fate. Nat Rev Mol Cell Biol 2019; 20: 199-210. doi: 10.1038/s41580-019-0110-x Hafner A Bulyk ML Jambhekar A Lahav G The multiple mechanisms that regulate p53 activity and cell fate. Nat Rev Mol Cell Biol 2019 20 199 210 doi 10.1038/s41580-019-0110-xOpen DOISearch in Google Scholar

30 Marx A, Belharazem D, Lee DH, Popovic ZV, Reissfelder C, Schalke B, et al. Molecular pathology of thymomas: implications for diagnosis and therapy. Virchows Arch 2021; 478: 101-10. doi: 10.1007/s00428-021-03068-8 Marx A Belharazem D Lee DH Popovic ZV Reissfelder C Schalke B et al Molecular pathology of thymomas: implications for diagnosis and therapy. Virchows Arch 2021 478 101 10 doi 10.1007/s00428-021-03068-8Open DOISearch in Google Scholar

31 Chen K, Che JM, Zhang XF, Jin RS, Xiang J, Han DP, et al. Next-generation sequencing in thymic epithelial tumors uncovered novel genomic aberration sites and strong correlation between TMB and MSH6 single nucleotide variations. Cancer Letters 2020; 476: 75-86. doi: 10.1016/j.canlet.2020.02.001 Chen K Che JM Zhang XF Jin RS Xiang J Han DP et al Next-generation sequencing in thymic epithelial tumors uncovered novel genomic aberration sites and strong correlation between TMB and MSH6 single nucleotide variations. Cancer Letters 2020 476 75 86 doi 10.1016/j.canlet.2020.02.001Open DOISearch in Google Scholar

32 Xu S, Li XF, Zhang HY, Zu LL, Yang LQ, Shi T, et al. Frequent genetic alterations and their clinical significance in patients with thymic epithelial tumors. Front Oncol 2021; 11: 667148. doi: 10.3389/fonc.2021.667148 Xu S Li XF Zhang HY Zu LL Yang LQ Shi T et al Frequent genetic alterations and their clinical significance in patients with thymic epithelial tumors. Front Oncol 2021 11 667148 doi 10.3389/fonc.2021.667148Open DOISearch in Google Scholar

33 Jovanovic D, Markovic J, Ceriman V, Peric J, Pavlovic S, Soldatovic I. Correlation of genomic alterations and PD-L1 expression in thymoma. J Thorac Dis 2020; 12: 7561-70. doi: 10.21037/jtd-2019-thym-13 Jovanovic D Markovic J Ceriman V Peric J Pavlovic S Soldatovic I Correlation of genomic alterations and PD-L1 expression in thymoma. J Thorac Dis 2020 12 7561 70 doi 10.21037/jtd-2019-thym-13Open DOISearch in Google Scholar

34 Enkner F, Pichlhöfer B, Zaharie AT, Krunic M, Holper TM, Janik S, et al. Molecular profiling of thymoma and thymic carcinoma: genetic differences and potential novel therapeutic targets. Pathol Oncol Res 2017; 23: 551-64. doi: 10.1007/s12253-016-0144-8 Enkner F Pichlhöfer B Zaharie AT Krunic M Holper TM Janik S et al Molecular profiling of thymoma and thymic carcinoma: genetic differences and potential novel therapeutic targets. Pathol Oncol Res 2017 23 551 64 doi 10.1007/s12253-016-0144-8Open DOISearch in Google Scholar

35 Rajan A, Girard N, Marx A. State of the art of genetic alterations in thymic epithelial tumors. J Thorac Oncol 2014; 9: S131-S6. doi: 10.1097/JTO.0000000000000298 Rajan A Girard N Marx A State of the art of genetic alterations in thymic epithelial tumors. J Thorac Oncol 2014 9 S131 S6 doi 10.1097/JTO.0000000000000298Open DOISearch in Google Scholar

36 Sakane T, Murase T, Okuda K, Saida K, Masaki A, Yamada T, et al. A mutation analysis of the EGFR pathway genes, RAS, EGFR, PIK3CA, AKT1 and BRAF, and TP53 gene in thymic carcinoma and thymoma type A/B3. Histopathology 2019; 75: 755-66. doi: 10.1111/his.13936 Sakane T Murase T Okuda K Saida K Masaki A Yamada T et al A mutation analysis of the EGFR pathway genes, RAS, EGFR, PIK3CA, AKT1 and BRAF, and TP53 gene in thymic carcinoma and thymoma type A/B3. Histopathology 2019 75 755 66 doi 10.1111/his.13936Open DOISearch in Google Scholar